Therapeutic approaches for T790M mutation positive non-small-cell lung cancer

被引：25
|
作者：
Attili, Ilaria [1 ]
Karachaliou, Niki [2 ,3 ]
Conte, PierFranco [1 ]
Bonanno, Laura [4 ]
Rosell, Rafael [3 ,5 ,6 ,7 ]
机构：
[1] Univ Padua, Dept Surg Oncol & Gastroenterol Sci, Padua, Italy
[2] Univ Hosp Sagrat Cor, Inst Oncol Dr Rosell IOR, Barcelona, Spain
[3] Quiron Dexeus Univ Inst, Coyote Res Grp, Pangaea Oncol, Mol Biol Lab, Barcelona, Spain
[4] IRCCS, Ist Oncol Veneto, Med Oncol 2, Padua, Italy
[5] Inst Invest Ciencies Germans Trias & Pujol, Badalona, Spain
[6] Quiron Dexeus Univ Inst, Inst Oncol Dr Rosell IOR, Barcelona, Spain
[7] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Badalona, Spain
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2018年 / 18卷 / 10期
关键词：
EGFR; lung cancer; osimertinib; TKI resistance; liquid biopsy; GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE INHIBITORS; 3RD-GENERATION EGFR INHIBITORS; ACQUIRED-RESISTANCE; MET AMPLIFICATION; OPEN-LABEL; OSIMERTINIB AZD9291; 1ST-LINE TREATMENT; TKI RESISTANCE; PHASE-III;
D O I：
10.1080/14737140.2018.1508347
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Introduction: Epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) is a subset of lung cancer with demonstrated response to targeted therapies. However, resistance to the first targeted approach usually occurs within the first year, and it is associated in 50-60% of cases to the T790M resistance mutation.Areas covered: The review provides an overview on the significance of the presence of the T790M mutation, its detection, treatment options and subsequent mechanisms of resistance.Expert commentary: Osimertinib is the current treatment option for T790M mutation positive NSCLC after progression to first or second-generation EGFR TKIs, with activity also on brain metastasis. However, the scenario is in continuous evolution and results from clinical trials are awaited in first-line setting and in combination strategies.
引用
收藏
页码：1021 / 1030
页数：10
相关论文
共 50 条
  • [1] Targeting the EGFR T790M mutation in non-small-cell lung cancer
    Normanno, Nicola
    Maiello, Monica Rosaria
    Chicchinelli, Nicoletta
    Iannaccone, Alessia
    Esposito, Claudia
    De Cecio, Rossella
    D'alessio, Amelia
    De Luca, Antonella
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2017, 21 (02) : 159 - 165
  • [2] The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer
    Gao, Xin
    Le, Xiuning
    Costa, Daniel B.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (04) : 383 - 390
  • [3] Real-world osimertinib for EGFR mutation-positive non-small-cell lung cancer with acquired T790M mutation
    Imamura, Fumio
    Kimura, Madoka
    Yano, Yukihiro
    Mori, Masahide
    Suzuki, Hidekazu
    Hirashima, Tomonori
    Ihara, Shouichi
    Komuta, Kiyoshi
    Shiroyama, Takayuki
    Nagatomo, Izumi
    Kumagai, Toru
    FUTURE ONCOLOGY, 2020, 16 (21) : 1537 - 1546
  • [4] Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer
    Soejima, Kenzo
    Yasuda, Hiroyuki
    Hirano, Toshiyuki
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (01) : 31 - 38
  • [5] Practical use of osimertinib in Japanese patients with EGFR T790M mutation positive advanced non-small-cell lung cancer
    Kotake, M.
    Murakami, H.
    Naito, T.
    Takahashi, T.
    Kenmotsu, H.
    Ono, A.
    Wakuda, K.
    Nakashima, K.
    Omori, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [6] Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status
    Nakashima, Kazuhisa
    Kimura, Madoka
    Akamatsu, Hiroaki
    Daga, Haruko
    Imai, Hisao
    Taira, Tetsuhiko
    Ko, Ryo
    Hisamatsu, Yasushi
    Nishino, Kazumi
    Sugimoto, Takeya
    Miyashita, Yosuke
    Takahashi, Toshiaki
    Kumagai, Toru
    Yamamoto, Nobuyuki
    Murakami, Haruyasu
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (07) : 671 - 675
  • [7] Docetaxel for non-small-cell lung cancer harboring the activated EGFR mutation with T790M at initial presentation
    Yamane, Hiromichi
    Ochi, Nobuaki
    Yasugi, Masayuki
    Tabayashi, Takayuki
    Yamagishi, Tomoko
    Monobe, Yasumasa
    Hisamoto, Akiko
    Kiura, Katsuyuki
    Takigawa, Nagio
    ONCOTARGETS AND THERAPY, 2013, 6 : 155 - 160
  • [8] Detection of EGFR T790M mutation in non-small-cell lung cancer patients using colony hybridization assay
    Fujita, Yoshihiko
    Suda, Kenichi
    Kimura, Hideharu
    Matsumoto, Kazuko
    Arao, Tokuzo
    Nagai, Tomoyuki
    Hayashi, Hidetoshi
    Furuta, Kazuyuki
    Kato, Hiroaki
    Saijo, Nagahiro
    Yatabe, Yasushi
    Mitsudomi, Tetsuya
    Nishio, Kazuto
    CANCER RESEARCH, 2012, 72
  • [9] Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer who have poor performance status
    Kimura, Madoka
    Nishino, Kazumi
    Imamura, Fumio
    Nakashima, Kazuhisa
    Takahashi, Toshiaki
    Sugimoto, Takeya
    Akamatsu, Hiroaki
    Yamamoto, Nobuyuki
    Daga, Haruko
    Imai, Hisao
    Taira, Tetsuhiko
    Miyashita, Yosuke
    Ko, Ryo
    Hisamatsu, Yasushi
    Murakami, Haruyasu
    ANNALS OF ONCOLOGY, 2018, 29
  • [10] An evaluation of aumolertinib for the treatment of EGFR T790M mutation-positive non-small cell lung cancer
    Wang, Jingyi
    Wu, Lin
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (06) : 647 - 652
12345